- 英文名称
- Atosiban Acetate
- 分子式
- C45H71N11O14S2
- 分子量
- 1054.24
- 中文别名
- 阿托西班醋酸盐; 阿托西班乙酸酯; (S)-N-((S)-5-氨基-1-((2-氨基-2-氧代乙基)氨基)-1-氧代戊烷-2-基)-1-((4R,7S,10S,13S,16R)-7-(2-氨基-2-氧代乙基)-13-((S)-仲丁基)-16-(4-乙氧基苄基)-10-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫基-5,8,11,14,17-五氮杂环二十烷-4-羰基)吡咯烷-2-甲酰胺乙酸盐; 1-{[7-(2-Amino-2-oxoethyl)-13-sec-butyl-16-(4-ethoxybenzyl)-10-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolylornithylglycinamide acetate (1:1); 1-({(4R,7S,10S,13S,16R)-7-(2-Amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide acetate (1:1); Glycinamide, 1-[[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]-L-prolyl-L-ornithyl-, acetate (1:1) (salt); 1-({(4R,7S,10S,13S,16R)-7-(2-Amino-2-oxoethyl)-13-[(2S)-2-butanyl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide acetate (1:1); (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide; (2S)-N-((S)-5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,16R)-7-(2-amino-2-oxoethyl)-13-((S)-sec-butyl)-16-(4-ethoxybenzyl)-10-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide acetate; Atosiban acetate
- 用途
- 作为九肽类竞争性加压素/催产素受体拮抗剂，主要用于自发早产的研究；体外可抑制催产素介导的肌细胞膜IP3释放、减少肌细胞内质网钙释放及细胞外钙内流、抑制催产素介导的蜕膜PGE和PGF释放；体内可影响精氨酸加压素对母胎心血管和肾脏系统的生理作用，在妊娠晚期绵羊中给药1小时未引起母胎心血管变化，可阻断小鼠臂旁核中催产素受体表达神经元的激活
